Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy.
Duell J, Leipold AM, Appenzeller S, Fuhr V, Rauert-Wunderlich H, Da Via M, Dietrich O, Toussaint C, Imdahl F, Eisele F, Afrin N, Grundheber L, Einsele H, Weinhold N, Rosenwald A, Topp MS, Saliba AE, Rasche L. Duell J, et al. Among authors: topp ms. Blood. 2024 Feb 22;143(8):685-696. doi: 10.1182/blood.2023021672. Blood. 2024. PMID: 37976456
Lymphoma-Sink Effect in Marginal Zone Lymphoma Based on CXCR4-Targeted Molecular Imaging.
Kosmala A, Seifert S, Schneid S, Dreher N, Higuchi T, Weich A, Serfling SE, Hartrampf PE, Einsele H, Buck AK, Topp MS, Duell J, Werner RA. Kosmala A, et al. Among authors: topp ms. Mol Imaging Biol. 2023 Aug;25(4):758-764. doi: 10.1007/s11307-023-01830-9. Epub 2023 Jun 7. Mol Imaging Biol. 2023. PMID: 37286923 Free PMC article.
Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma.
Duell J, Buck AK, Hartrampf PE, Schlötelburg W, Schneid S, Weich A, Dreher N, Lapa C, Kircher M, Higuchi T, Samnick S, Serfling SE, Raderer M, Rasche L, Einsele H, Topp MS, Kosmala A, Werner RA. Duell J, et al. Among authors: topp ms. J Nucl Med. 2023 Dec 1;64(12):1889-1894. doi: 10.2967/jnumed.123.266074. J Nucl Med. 2023. PMID: 37797975 Free article.
Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [18F]FDG.
Kosmala A, Duell J, Schneid S, Serfling SE, Higuchi T, Weich A, Lapa C, Hartrampf PE, Raderer M, Einsele H, Buck AK, Topp MS, Schlötelburg W, Werner RA. Kosmala A, et al. Among authors: topp ms. Eur J Nucl Med Mol Imaging. 2024 Feb;51(3):749-755. doi: 10.1007/s00259-023-06489-6. Epub 2023 Nov 9. Eur J Nucl Med Mol Imaging. 2024. PMID: 37943339 Free PMC article.
CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges.
Werner R, Haug A, Buske C, Heidegger S, Illert AL, Bassermann F, Herhaus P, Buck A, Duell J, Topp MS, Kraus S, Einsele H, Lapa C, Raderer M, Lenz G, Habringer S, von Tresckow B, Keller U. Werner R, et al. Among authors: topp ms. Nuklearmedizin. 2024 Apr;63(2):57-61. doi: 10.1055/a-2194-9965. Epub 2024 Jan 8. Nuklearmedizin. 2024. PMID: 38190998 Free PMC article.
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Brouwer-Visser J, Fiaschi N, Deering RP, Cygan KJ, Scott D, Jeong S, Boucher L, Gupta NT, Gupta S, Adler C, Topp MS, Bannerji R, Duell J, Advani RH, Flink DM, Chaudhry A, Thurston G, Ambati SR, Jankovic V. Brouwer-Visser J, et al. Among authors: topp ms. J Immunother Cancer. 2024 Mar 21;12(3):e008338. doi: 10.1136/jitc-2023-008338. J Immunother Cancer. 2024. PMID: 38519055 Free PMC article.
Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study.
Zhou X, Wagner V, Scheller L, Stanojkovska E, Riedhammer C, Xiao X, Steinhardt MJ, Vogt C, Nerreter S, Eisele F, John M, Munawar U, Kadel SK, Mersi J, Ruckdeschel A, Schimanski S, Haertle L, Waldschmidt JM, Han S, Topp M, Duell J, Einsele H, Riedel A, Kortüm KM, Rasche L. Zhou X, et al. Br J Haematol. 2024 Sep;205(3):999-1010. doi: 10.1111/bjh.19515. Epub 2024 May 8. Br J Haematol. 2024. PMID: 38719214
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: Primary analysis of the ELM-1 study.
Topp MS, Matasar MJ, Allan JN, Ansell SM, Barnes JA, Arnason JE, Michot JM, Goldschmidt N, O'Brien SM MD, Abadi U, Avivi I, Cheng Y, Flink DM, Zhu M, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Crombie JL. Topp MS, et al. Blood. 2024 Dec 30:blood.2024027044. doi: 10.1182/blood.2024027044. Online ahead of print. Blood. 2024. PMID: 39786390
128 results